BioSpace News Archive

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the fourth quarter and full-year 2020 ended December 31, 2020, on Thursday, February 25, 2021, before the opening of the financial markets.

Appoints Owen Wallace, Ph.D., as Chief Scientific Officer Silvia Buonamici, Ph.D., joins as Senior Vice President, Drug Discovery Biology

Signifier Medical Technologies, an innovator in the sleep disordered breathing market, today announced that eXciteOSA®, the first and only daytime intraoral neuromuscular stimulation device for treating mild obstructive sleep apnea and snoring, has been cleared by the U.S. Food and Drug Administration (FDA), giving millions of sufferers in the U.S. access to this innovative therapy.

BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure (CHF) via Transcatheter based Ventricular Restoration (TCVR), today announced that the German Institute for Hospital Remuneration (InEK) has renewed the NUB Status 1 reimbursement designation in Germany for the Revivent TC™ TransCatheter Ventricular Enhancement System used in LIVE™ Therapy (Less Invasive Ventricular Enhancement).

COVAXX, a U.S. company developing UB-612, a multitope protein/synthetic peptide-based vaccine to fight COVID-19, today announced positive interim Phase 1 data from its open-label COVID-19 clinical trial conducted in Taiwan.

Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced a new research program for an oral glucagon-like peptide-2 (GLP-2) analog based on the Company’s platform technology

Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced the exercise of a portion of the warrants from its October 2020 financing

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer’s disease, today announced significant program progress and expected milestones for 2021.

SmartBreast Corporation (SmartBreast™), a privately held company focused on breast cancer screening and diagnosis, announced today that it has acquired the Discovery NM750b Molecular Breast Imaging (MBI) assets from GE Healthcare,

Today, the Sarah Cannon Transplant and Cellular Therapy Network, formerly the Sarah Cannon Blood Cancer Network, announced 19 abstracts and presentations have been accepted for presentation at the 2021 TCT | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, held virtually from February 8-12, 2021.